The goal of the Texas Alzheimer's Research and Care Consortium (TARCC) is to advance research efforts in Texas that lead to better diagnosis, treatment, and prevention of Alzheimer's disease (AD). TARCC researchers are aggressively pursuing a number of cutting-edge objectives aimed at improving the efficiency of early diagnosis, understanding the disease mechanisms at work in Alzheimer's, and uncovering effective disease prevention.
Since 2007 a four (4) member External Advisory Committee comprised of out-of state distinguished, nationally prominent research scientists and medical doctors led by Dr. Ron Petersen-Mayo Clinic have regularly met with Steering Committee representatives to conduct a detailed review of all TARCC scientific activities and grant awards to assure that the investments made by the Texas Legislature are advancing the science of AD research.
The objectives of TARCC are to pursue investigator initiated and collaborative research studies to answer questions related to the role of biological and clinical markers for inflammation, cardiovascular factors, hyperinsulinemia, and other risk factors in the development and progression of AD. These factors will be investigated longitudinally and with regard to how they may differ between Hispanic and non-Hispanic citizens of Texas. Additional objectives relate to achieving and maintaining clinical sample sizes and longitudinal follow-up targets, as well as maintaining overall data quality and protocol fidelity. The following aims are adopted with the understanding that additional funds from state or extramural sources will be required to pursue research activities beyond bio-banking and maintenance of the clinical cohorts and dataset.
Specific Research Aims
Maintain a longitudinal database of clinical and biological data from participants diagnosed with AD, MCI or normal controls.